Sophiris Bio Inc. (SPHS)’s Financial Results Comparing With Concert Pharmaceuticals Inc. (NASDAQ:CNCE)

Sophiris Bio Inc. (NASDAQ:SPHS) and Concert Pharmaceuticals Inc. (NASDAQ:CNCE) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sophiris Bio Inc. 1 0.00 N/A -0.19 0.00
Concert Pharmaceuticals Inc. 12 236.89 N/A -3.13 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.


Table 2 provides the return on equity, net margins and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Sophiris Bio Inc. 0.00% 582.1% -40.2%
Concert Pharmaceuticals Inc. 0.00% -41.7% -36.5%

Risk & Volatility

Sophiris Bio Inc. has a beta of 2.86 and its 186.00% more volatile than Standard & Poor’s 500. From a competition point of view, Concert Pharmaceuticals Inc. has a 0.83 beta which is 17.00% less volatile compared to Standard & Poor’s 500.


The Current Ratio and a Quick Ratio of Sophiris Bio Inc. are 2 and 2. Competitively, Concert Pharmaceuticals Inc. has 20.4 and 20.4 for Current and Quick Ratio. Concert Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Sophiris Bio Inc.

Analyst Recommendations

In next table is given Sophiris Bio Inc. and Concert Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sophiris Bio Inc. 0 0 3 3.00
Concert Pharmaceuticals Inc. 0 0 5 3.00

The average target price of Sophiris Bio Inc. is $4.83, with potential upside of 550.33%. Meanwhile, Concert Pharmaceuticals Inc.’s average target price is $23.2, while its potential upside is 116.22%. Based on the analysts view we can conclude, Sophiris Bio Inc. is looking more favorable than Concert Pharmaceuticals Inc.

Institutional and Insider Ownership

The shares of both Sophiris Bio Inc. and Concert Pharmaceuticals Inc. are owned by institutional investors at 7.7% and 81.8% respectively. Insiders owned 0.85% of Sophiris Bio Inc. shares. Insiders Comparatively, owned 3.2% of Concert Pharmaceuticals Inc. shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sophiris Bio Inc. -1.98% 21.82% 10.61% -11.61% -65.26% 19.28%
Concert Pharmaceuticals Inc. -4.55% -16.72% -1.28% -29.5% -38.24% -19.84%

For the past year Sophiris Bio Inc. had bullish trend while Concert Pharmaceuticals Inc. had bearish trend.

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The companyÂ’s primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. The companyÂ’s clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with AlzheimerÂ’s disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis. It product candidates that have completed Phase 1 clinical trials comprise CTP-730 for use in the treatment of inflammation or cancer; JZP-386 for use in the treatment of excessive daytime sleepiness and cataplexy; and CTP-543 for use in the treatment of alopecia areata. The company has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.